Abstract:Prolactin binding to the prolactin receptor exerts pleiotropic biological effects in vertebrates. The prolactin receptor (PRLR) has multiple isoforms due to alternative splicing. The biological roles and related signaling of the long isoform (PRLR-LF) have been fully elucidated. However, little is known about the short isoform (PRLR-SF), particularly in cancer development and metabolic reprogramming, a core hallmark of cancer. Here, we reveal the role and underlying mechanism of PRLR-SF in pancreatic ductal adenocarcinoma (PDAC). Methods: A human PDAC tissue array was used to investigate the clinical relevance of PRLR in PDAC. The in vivo implications of PRLR-SF in PDAC were examined in a subcutaneous xenograft model and an orthotopic xenograft model. Immunohistochemistry was performed on tumor tissue obtained from genetically engineered KPC (KrasG12D/+; Trp53R172H/+; Pdx1-Cre) mice with spontaneous tumors. 13C-labeled metabolite measures, LC-MS, EdU incorporation assays and seahorse analyses were used to identify the effects of PRLR-SF on the pentose phosphate pathway and glycolysis. We identified the molecular mechanisms by immunofluorescence, coimmunoprecipitation, proximity ligation assays, chromatin immunoprecipitation and promoter luciferase activity. Public databases (TCGA, GEO and GTEx) were used to analyze the expression and survival correlations of the related genes. Results: We demonstrated that PRLR-SF is predominantly expressed in spontaneously forming pancreatic tumors of genetically engineered KPC mice and human PDAC cell lines. PRLR-SF inhibits the proliferation of PDAC cells (AsPC-1 and BxPC-3) in vitro and tumor growth in vivo. We showed that PRLR-SF reduces the expression of genes in the pentose phosphate pathway (PPP) and nucleotide biosynthesis by activating Hippo signaling. TEAD1, a downstream transcription factor of Hippo signaling, directly regulates the expression of G6PD and TKT, which are PPP rate-limiting enzymes. Moreover, NEK9 directly interacts with PRLR-SF and is the intermediator between PRLR and the Hippo pathway. The PRLR expression level is negatively correlated with overall survival and TNM stage in PDAC patients. Additionally, pregnancy and lactation increase the ratio of PRLR-SF:PRLR-LF in the pancreas of wild-type mice and subcutaneous PDAC xenograft tumors. Conclusion: Our characterization of the relationship between PRLR-SF signaling, the NEK9-Hippo pathway, PPP and nucleotide synthesis explains a mechanism for the correlation between PRLR-SF and metabolic reprogramming in PDAC progression. Strategies to alter this pathway might be developed for the treatment or prevention of pancreatic cancer.

Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion.

Phosphatase Activity, Trimerization, and the C-terminal Polybasic Region Are All Required for PRL1-mediated Cell Growth and Migration.

Phosphatase of Regenerating Liver-1 Regulates Wing Vein Formation Through TGF-β Pathway in Drosophila Melanogaster

PRL-1 Protein Promotes ERK1/2 and RhoA Protein Activation Through a Non-canonical Interaction with the Src Homology 3 Domain of P115 Rho GTPase-activating Protein*

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

PRL1 and PRL3 promote macropinocytosis via its lipid phosphatase activity

Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling

Phosphatase of Regenerating Liver-3 Localizes to Cyto-Membrane and is Required for B16F1 Melanoma Cell Metastasis in Vitro and in Vivo

Targeting PRL phosphatases in hematological malignancies

Mouse PRL-2 and PRL-3, Two Potentially Prenylated Protein Tyrosine Phosphatases Homologous to PRL-1

The PRL2 Phosphatase Upregulates miR-21 through Activation of the JAK2/STAT3 Pathway to Downregulate the PTEN Tumor Suppressor

Phosphatase of Regenerating Liver-3 Directly Interacts with Integrin Β1 and Regulates Its Phosphorylation at Tyrosine 783

Crystal structure and mechanistic studies of the PPM1D serine/threonine phosphatase catalytic domain

The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer

Phosphatase of Regenerating Liver-3 (PRL-3) is Associated with Metastasis and Poor Prognosis in Gastric Carcinoma

PRL2 Phosphatase Enhances Oncogenic FLT3 Signaling Via Dephosphorylation of the E3 Ubiquitin Ligase CBL at Tyrosine 371

Essential Phosphatases and A Phospho-Degron Are Critical for Regulation of Src-3/Aib1 Coactivator Function and Turnover

Tumor Metastasis-Associated Molecule PRL-3:structure,function and Possibility As the Target of Anti-Cancer Drugs

Prenylation-Dependent Association of Protein-Tyrosine Phosphatases Prl-1,-2, And-3 with the Plasma Membrane and the Early Endosome

Advances in Brief PRL-3 and PRL-1 Promote Cell Migration , Invasion , and Metastasis 1 , 2

Abstract 1971: Small C-terminal Domain Phosphatase 1 Stabilizes PML to Regulate the Progression of Renal Clear Cell Carcinoma.